Facilitated PCI in patients with ST-elevation myocardial infarction.

Abstract

BACKGROUND:

We hypothesized that percutaneous coronary intervention (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improve outcomes in patients with acute ST-segment elevation myocardial infarction, as compared with abciximab administered immediately before the procedure (primary PCI).

METHODS:

In this international, double-blind, placebo-controlled study, we randomly assigned patients with ST-segment elevation myocardial infarction who presented 6 hours or less after the onset of symptoms to receive combination-facilitated PCI, abciximab-facilitated PCI, or primary PCI. All patients received unfractionated heparin or enoxaparin before PCI and a 12-hour infusion of abciximab after PCI. The primary end point was the composite of death from all causes, ventricular fibrillation occurring more than 48 hours after randomization, cardiogenic shock, and congestive heart failure during the first 90 days after randomization.

RESULTS:

A total of 2452 patients were randomly assigned to a treatment group. Significantly more patients had early ST-segment resolution with combination-facilitated PCI (43.9%) than with abciximab-facilitated PCI (33.1%) or primary PCI (31.0%; P=0.01 and P=0.003, respectively). The primary end point occurred in 9.8%, 10.5%, and 10.7% of the patients in the combination-facilitated PCI group, abciximab-facilitated PCI group, and primary-PCI group, respectively (P=0.55); 90-day mortality rates were 5.2%, 5.5%, and 4.5%, respectively (P=0.49).

CONCLUSIONS:

Neither facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab alone significantly improved the clinical outcomes, as compared with abciximab given at the time of PCI, in patients with ST-segment elevation myocardial infarction. (ClinicalTrials.gov number, NCT00046228 [ClinicalTrials.gov].)

• Authors: Stephen G Ellis, Michal Tendera, Mark A de Belder, Ad J van Boven, Petr Widimsky, Luc Janssens, H R Andersen, Amadeo Betriu, Stefano Savonitto, Jerzy Adamus, Jan Z Peruga, Maciej Kosmider, Olivier Katz, Thomas Neunteufl, Julia Jorgova, Maria Dorobantu, Liliana Grinfeld, Paul Armstrong, Bruce R Brodie, Howard C Herrmann, Gilles Montalescot, Franz-Josef Neumann, Mark B Effron, Elliot S Barnathan, Eric J Topol, FINESSE Investigators
• Journal: The New England journal of medicine (N Engl J Med) Vol. 358 Issue 21 Pg. 2205-17 (May 22 2008) ISSN: 1533-4406 [Electronic] United States
• PMID: 18499565 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2008 Massachusetts Medical Society.

Chemical References

• Antibodies, Monoclonal
• Fibrinolytic Agents
• Immunoglobulin Fab Fragments
• Recombinant Proteins
• reteplase
• Tissue Plasminogen Activator
• Abciximab

Topics

• Abciximab
• Aged
• Angioplasty, Balloon, Coronary
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Cerebral Infarction (chemically induced)
• Combined Modality Therapy
• Double-Blind Method
• Electrocardiography
• Female
• Fibrinolytic Agents (administration & dosage, adverse effects)
• Hemorrhage (chemically induced)
• Humans
• Immunoglobulin Fab Fragments (adverse effects, therapeutic use)
• Kaplan-Meier Estimate
• Male
• Myocardial Infarction (classification, complications, mortality, therapy)
• Recombinant Proteins (administration & dosage, adverse effects)
• Time Factors
• Tissue Plasminogen Activator (administration & dosage, adverse effects)
• Treatment Outcome